{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:18:33Z","timestamp":1778228313306,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s00415-020-10223-9","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T19:02:33Z","timestamp":1600196553000},"page":"923-935","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4"],"prefix":"10.1007","volume":"268","author":[{"given":"Bram","family":"De Wel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Goosens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atka","family":"Sobota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Van Camp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Geukens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Griet","family":"Van Kerschaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marl\u00e8ne","family":"Jagut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Claes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9937-443X","authenticated-orcid":false,"given":"Kristl G.","family":"Claeys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,15]]},"reference":[{"issue":"5","key":"10223_CR1","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","volume":"52","author":"K Zerres","year":"1995","unstructured":"Zerres K, Sch\u00f6neborn SR (1995) natural history in proximal spinal muscular atrophy: clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol 52(5):518\u2013523","journal-title":"Arch Neurol"},{"issue":"5","key":"10223_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","volume":"11","author":"E Mercuri","year":"2012","unstructured":"Mercuri E, Bertini E, Iannaccone ST (2012) Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol 11(5):443\u2013452","journal-title":"Lancet Neurol"},{"issue":"1","key":"10223_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00439-008-0598-1","volume":"125","author":"L Al\u00edas","year":"2009","unstructured":"Al\u00edas L, Bernal S, Fuentes-Prior P, Barcel\u00f3 MJ, Also E, Mart\u00ednez-Hern\u00e1ndez R et al (2009) Mutation update of spinal muscular atrophy in Spain: Molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene. Hum Genet 125(1):29\u201339","journal-title":"Hum Genet"},{"key":"10223_CR4","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1007\/s00018-018-2849-1","volume":"75","author":"H Chaytow","year":"2018","unstructured":"Chaytow H, Huang Y, Gillingwater TH, Faller KME (2018) The role of survival motor neuron protein (SMN) in protein homeostasis. Cell Mol Life Sci 75:3877\u20133894","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"10223_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/hmg\/9.2.259","volume":"9","author":"CL Lorson","year":"2000","unstructured":"Lorson CL, Androphy EJ (2000) An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet 9(2):259\u2013266","journal-title":"Hum Mol Genet"},{"issue":"10063","key":"10223_CR6","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC et al (2016) Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388(10063):3017\u20133026","journal-title":"Lancet"},{"issue":"4","key":"10223_CR7","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","volume":"26","author":"NK Singh","year":"2006","unstructured":"Singh NK, Singh NN, Androphy EJ, Singh RN (2006) Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 26(4):1333\u20131346","journal-title":"Mol Cell Biol"},{"issue":"18","key":"10223_CR8","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J et al (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377(18):1723\u20131732","journal-title":"N Engl J Med"},{"issue":"7","key":"10223_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM et al (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 378(7):625\u2013635","journal-title":"N Engl J Med"},{"issue":"4","key":"10223_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","volume":"6","author":"MC Walter","year":"2019","unstructured":"Walter MC, Wenninger S, Thiele S, Stauber J, Hiebeler M, Greckl E et al (2019) Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3: a prospective observational study. J Neuromuscul Dis 6(4):453\u2013465","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"10223_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker T, Wurster CD, G\u00fcnther R, Schreiber-Katz O, Osmanovic A, Petri S et al (2020) Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol 19(4):317\u2013325","journal-title":"Lancet Neurol"},{"issue":"1","key":"10223_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/mus.10166","volume":"26","author":"L Merlini","year":"2002","unstructured":"Merlini L, Mazzone ES, Solari A, Morandi L (2002) Reliability of hand-held dynamometry in spinal muscular atrophy. Muscle Nerve 26(1):64\u201370","journal-title":"Muscle Nerve"},{"key":"10223_CR13","first-page":"4","volume":"10","author":"AM Seferian","year":"2015","unstructured":"Seferian AM, Moraux A, Canal A, Decostre V, Diebate O, Le Moing AG et al (2015) Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: An observational multicenter trial. PLoS ONE 10:4","journal-title":"PLoS ONE"},{"issue":"11","key":"10223_CR14","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/mus.880141111","volume":"14","author":"RP Kleyweg","year":"1991","unstructured":"Kleyweg RP, Van Der Mech\u00e9 FGA, Schmitz PIM (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barr\u00e9 syndrome. Muscle Nerve 14(11):1103\u20131109","journal-title":"Muscle Nerve"},{"issue":"5","key":"10223_CR15","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/mus.25120","volume":"54","author":"S Dunaway Young","year":"2016","unstructured":"Dunaway Young S, Montes J, Kramer SS, Marra J, Salazar R, Cruz R et al (2016) Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve 54(5):836\u2013842","journal-title":"Muscle Nerve"},{"issue":"9\u201310","key":"10223_CR16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","volume":"17","author":"JM O\u2019Hagen","year":"2007","unstructured":"O\u2019Hagen JM, Glanzman AM, McDermott MP, Ryan PA, Flickinger J, Quigley J et al (2007) An expanded version of the Hammersmith functional motor scale for SMA II and III patients. Neuromuscul Disord 17(9\u201310):693\u2013697","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10223_CR17","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J, Ramsey D, Fanelli L, Young SD et al (2017) Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve 55(6):869\u2013874","journal-title":"Muscle Nerve"},{"issue":"6","key":"10223_CR18","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1183\/09031936.00080312","volume":"40","author":"PH Quanjer","year":"2012","unstructured":"Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH et al (2012) Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations. Eur Respir J 40(6):1324\u20131343","journal-title":"Eur Respir J"},{"issue":"3","key":"10223_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.nmd.2015.12.004","volume":"26","author":"CS Batcho","year":"2016","unstructured":"Batcho CS, Van den Bergh P, Van Damme P, Roy AJ, Thonnard JL, Penta M et al (2016) How robust is ACTIVLIM for the follow-up of activity limitations in patients with neuromuscular diseases? Neuromuscul Disord 26(3):211\u2013220","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10223_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2753.2010.01513.x","volume":"18","author":"P Banks","year":"2012","unstructured":"Banks P, Martin CR, Petty RKH (2012) The factor structure of the SF-36 in adults with progressive neuromuscular disorders. J Eval Clin Pract 18(1):32\u201336","journal-title":"J Eval Clin Pract"},{"key":"10223_CR21","first-page":"1","volume-title":"Pharmaceuticalsciences encyclopedia","author":"AA Levin","year":"2010","unstructured":"Levin AA, Henry SP (2010) Toxicology of oligonucleotide therapeutics and understanding the relevance of the toxicities. In: Gad SC (ed), Pharmaceuticalsciences encyclopedia, p 1\u201338"},{"issue":"4","key":"10223_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1089\/nat.2015.0598","volume":"26","author":"JA Engelhardt","year":"2016","unstructured":"Engelhardt JA (2016) Comparative renal toxicopathology of antisense oligonucleotides. Nucleic Acid Ther 26(4):199\u2013209","journal-title":"Nucleic Acid Ther"},{"issue":"3","key":"10223_CR23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/mus.21420","volume":"40","author":"L Viollet","year":"2009","unstructured":"Viollet L, Gailey S, Thornton DJ, Friedman NR, Flanigan KM, Mahan JD et al (2009) Utility of cystatin C to monitor renal function in duchenne muscular dystrophy laurence. Muscle Nerve 40(3):438\u2013442","journal-title":"Muscle Nerve"},{"issue":"1","key":"10223_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/0192623314551840","volume":"43","author":"KS Frazier","year":"2015","unstructured":"Frazier KS (2015) Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist\u2019s perspective. Toxicol Pathol 43(1):78\u201389","journal-title":"Toxicol Pathol"},{"key":"10223_CR25","doi-asserted-by":"crossref","unstructured":"Biogen Idec Ireland. Spinraza (nusinersen): communicating hydrocephalus not related to meningitis or bleeding reported. Internet Document: [3 pages], 31 Jul 2018. Reactions Weekly 1714, 3. Available from: https:\/\/www.hpra.ie\/docs\/default-source\/default-document-library\/important-safetyinformation","DOI":"10.1007\/s40278-018-50183-2"},{"key":"10223_CR26","first-page":"1","volume":"2020","author":"RI Wadman","year":"2020","unstructured":"Wadman RI, van der Pol WL, Bosboom WMJ, Asselman FL, van den Berg LH, Iannaccone ST et al (2020) Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst Rev 2020:1","journal-title":"Cochrane Database Syst Rev"},{"key":"10223_CR27","unstructured":"Koch BM, Simenson RL (1992). Upper extremity strength and function in children with spinal muscular atrophy type II. Arch Phys Med Rehabil 73"},{"issue":"1","key":"10223_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.nmd.2009.11.008","volume":"20","author":"U Werlauff","year":"2010","unstructured":"Werlauff U, Steffensen BF, Bertelsen S, Fl\u00f8ytrup I, Kristensen B, Werge B (2010) Physical characteristics and applicability of standard assessment methods in a total population of spinal muscular atrophy type II patients. Neuromuscul Disord 20(1):34\u201343","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10223_CR29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/ene.13534","volume":"25","author":"RI Wadman","year":"2018","unstructured":"Wadman RI, Wijngaarde CA, Stam M, Bartels B, Otto LAM, Lemmink HH et al (2018) Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c\u20134. Eur J Neurol 25(3):512\u2013518","journal-title":"Eur J Neurol"},{"issue":"3","key":"10223_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.nmd.2014.11.008","volume":"25","author":"S Sivo","year":"2015","unstructured":"Sivo S, Mazzone E, Antonaci L, De Sanctis R, Fanelli L, Palermo C et al (2015) Upper limb module in non-ambulant patients with spinal muscular atrophy: 12 month changes. Neuromuscul Disord 25(3):212\u2013215","journal-title":"Neuromuscul Disord"},{"key":"10223_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1371\/journal.pone.0012140","volume":"5","author":"KJ Swoboda","year":"2010","unstructured":"Swoboda KJ, Scott CB, Crawford TO, Simard LR, Reyna SP, Krosschell KJ et al (2010) SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of l-carnitine and valproic acid in spinal muscular atrophy. PLoS ONE 5:8","journal-title":"PLoS ONE"},{"issue":"1","key":"10223_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-017-0853-y","volume":"17","author":"S McGraw","year":"2017","unstructured":"McGraw S, Qian Y, Henne J, Jarecki J, Hobby K, Yeh WS (2017) A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurol 17(1):1\u20139","journal-title":"BMC Neurol"},{"issue":"1","key":"10223_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-020-01367-y","volume":"15","author":"CA Wijngaarde","year":"2020","unstructured":"Wijngaarde CA, Veldhoen ES, Van Eijk RPA, Stam M, Otto LAM, Asselman FL et al (2020) Natural history of lung function in spinal muscular atrophy. Orphanet J Rare Dis 15(1):1\u201311","journal-title":"Orphanet J Rare Dis"},{"key":"10223_CR34","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1007\/s00415-020-09847-8","volume":"267","author":"A Osmanovic","year":"2020","unstructured":"Osmanovic A, Ranxha G, Kumpe M, M\u00fcschen L, Binz C, Wiehler F et al (2020) Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy. J Neurol 267:2398\u20132407","journal-title":"J Neurol"},{"key":"10223_CR35","doi-asserted-by":"publisher","first-page":"117067","DOI":"10.1016\/j.jns.2020.117067","volume":"417","author":"A Barp","year":"2020","unstructured":"Barp A, Carraro E, Albamonte E, Salmin F, Lunetta C, Comi G Pietro et al. (2020) Muscle MRI in two SMA patients on nusinersen treatment: a two years follow-up. J Neurol Sci 417:117067. https:\/\/doi.org\/10.1016\/j.jns.2020.117067","journal-title":"J Neurol Sci"},{"issue":"10","key":"10223_CR36","doi-asserted-by":"publisher","first-page":"e4357","DOI":"10.1002\/nbm.4357","volume":"33","author":"LAM Otto","year":"2020","unstructured":"Otto LAM, van der Pol WL, Schlaffke L, Wijngaarde CA, Stam M, Wadman RI et al (2020) Quantitative MRI of skeletal muscle in a cross-sectional cohort of patients with spinal muscular atrophy types 2 and 3. NMR Biomed 33(10):e4357","journal-title":"NMR Biomed"},{"key":"10223_CR37","unstructured":"Safety team leader review NDA 209531 Spinraza (nusinersen) 2017 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/209531Orig1s000MedR.pdf [cited 2020 Jun 9]"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10223-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-020-10223-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10223-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T02:56:34Z","timestamp":1631674594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-020-10223-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10223"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-10223-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,15]]},"assertion":[{"value":"15 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KGC received advisory board honoraria from Alnylam, Biogen, CSL Behring, Sanofi-Genzyme and travel reimbursement from Sanofi-Genzyme, unrelated to this work. The other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Written informed consent was obtained from the patients. Both the Ethics Committee Research UZ\/KU Leuven and the Belgian Federal Agency for Medicines and Health Products (FAGG) approved the study (EudraCT-nr: 2019-005007-40), which has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}